Five things for pharma marketers to know: Monday, August 31

Kim Kardashian posts corrective information on Instagram and Twitter; DPP-4 inhibitors are linked to joint pain; doctors question off-label prescriptions of PCSK9 inhibitors

The FDA approves second PCSK9 inhibitor, Repatha

Amgen's Repatha will come to market priced $500 lower than the cost of Sanofi and Regeneron's Praluent.

Mobile Marketing: Dial M for Launch

Mobile is the multilayered ecosystem into which all products are now launched, so doing it right is crucial to commercial and outcomes success. James Chase ...
Welcome to CampaignCheckup! CampaignCheckup is our new, monthly podcast series dedicated to examining the curious in Rx marketing and advertising. For our inaugural episode, "Cardiac Resuscitation," Larry Dobrow, senior editor, MM&M, and Michael Maher, president, ID Health, sit down to discuss the DTC campaign for Bristol-Myers Squibb's and Pfizer's oral blood thinner Eliquis.

Latest

Five things for pharma marketers to know: Friday, August 28

Five things for pharma marketers to know: Friday, August 28

Amgen's Repatha receives FDA nod; Mylan shareholders vote in favor of Perrigo deal; doctors push for below-average price of experimental cancer drug

Washington Insider: A New Report

Washington Insider: A New Report

Back Talk: Hail to the . . . CEO?

Back Talk: Hail to the . . . CEO?

Private View: Bonnie Overton

Private View: Bonnie Overton

Partner Forum: Will predictive analytics sell?

Can predictive analytics, embedded into CRM, fulfill the promise on which closed-loop marketing fell short: Allow pharma to harness data from rep visits to make their upcoming digital sales pitches smarter?

Sunovion prepares for FDA decision on Aptiom

Sunovion prepares for FDA decision on Aptiom

The FDA is expected to announce this week whether it has approved the epilepsy drug as a monotherapy for partial-onset seizures.

Five things for pharma marketers to know: Thursday, August 27

Five things for pharma marketers to know: Thursday, August 27

The FDA releases biosimilar-naming draft guidance; PD1 drugs linked to a rare type of diabetes; Amgen's PCSK9 inhibitor faces approval decision

Social Engagement: Leveling the Field

Social Engagement: Leveling the Field

Social media has the potential to elevate challenger brands to the highest step on the podium. But with many companies still languishing in the blocks, medal-worthy performances remain few and far between. It's time for pharma to step up its social game, as James Chase reports

What Wearables Can Deliver for Marketers

What Wearables Can Deliver for Marketers

Excitement about wearables like the Apple Watch or Fitbit sometimes fuels unrealistic hype about healthcare marketing opportunities.

CHC and CCC partner to offer regulatory education to agencies

CHC and CCC partner to offer regulatory education to agencies

The compliance "university" aims to help healthcare agencies and publishers stay up to date on the latest regulatory changes.

Five things for pharma marketers to know: Wednesday, August 26

Five things for pharma marketers to know: Wednesday, August 26

Medicaid officials urged to expand access to hepatitis-C drugs; Perrigo is looking to make acquisitions; Sarepta's experimental therapy gets priority review

Agency Spotlight



Email Newsletters


Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.